18:27 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Roche discontinues SMA candidate

Roche (SIX:ROG; OTCQX:RHHBY) said it will discontinue development of spinal muscular atrophy candidate olesoxime (RG6083, TRO19622). In April, Roche presented data at the American Academy of Neurology meeting in Los Angeles from the long-term follow-up...
21:08 , Jun 1, 2018 |  BC Extra  |  Company News

Roche discontinues SMA candidate

Roche (SIX:ROG; OTCQX:RHHBY) said it will discontinue development of spinal muscular atrophy candidate olesoxime (RG6083, TRO19622). In April, Roche presented data at the American Academy of Neurology meeting in Los Angeles from the long-term follow-up...
18:11 , Mar 9, 2018 |  BC Week In Review  |  Company News

Roivants new subsidiary adds Ligand asset

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted exclusive, worldwide rights for diabetes candidate RVT-1502 (formerly LGD-6972) to the newly created Metavant Sciences subsidiary of Roivant Sciences GmbH (Basel, Switzerland). Roivant has established at least six subsidiaries, which...
23:30 , Mar 7, 2018 |  BC Extra  |  Company News

Roivant unveils new subsidiary on deal with Ligand

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted exclusive, worldwide rights for diabetes candidate RVT-1502 (formerly LGD-6972) to the newly created Metavant Sciences subsidiary of Roivant Sciences GmbH (Basel, Switzerland). Roivant has established at least six subsidiaries, which...
17:24 , Feb 16, 2018 |  BC Week In Review  |  Company News

Poxel, Roivant partner for T2D in U.S., EU

Poxel S.A. (Euronext:POXEL) granted Roivant Sciences GmbH (Basel, Switzerland) rights to late-stage Type II diabetes candidate imeglimin (PXL008). Poxel will receive an upfront payment of $35 million and is eligible for up to $600 million...
21:40 , Feb 12, 2018 |  BC Extra  |  Company News

Poxel finds U.S., European partner for imeglimin

Poxel S.A. (Euronext:POXEL) added €0.65 (10%) to €6.87 on Monday after granting Roivant Sciences GmbH (Basel, Switzerland) rights to late-stage Type II diabetes candidate imeglimin (PXL008). Poxel will receive an upfront payment of $35 million...
22:58 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Poxel, Sumitomo launch Phase III program of imeglimin in diabebetes

Poxel S.A. (Euronext:POXEL) and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) began the double-blind, placebo-controlled, 24-week Japanese Phase III TIMES I trial of imeglimin (PXL008) to treat Type II diabetes. It is the first of three...
18:58 , Nov 3, 2017 |  BC Week In Review  |  Company News

Sumitomo gains Asian rights to Poxel's diabetes candidate

Poxel S.A. (Euronext:POXEL) granted Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) exclusive rights to Type II diabetes candidate imeglimin (PXL008) in Japan, China, South Korea, Taiwan and nine Southeast Asian countries. In Japan, Phase III development...
22:05 , Oct 30, 2017 |  BC Extra  |  Company News

Sumitomo gains Asian rights to Poxel's imeglimin

Poxel S.A. (Euronext:POXEL) jumped €2.16 (40%) to €7.55 on Monday after granting Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) rights to Type II diabetes candidate imeglimin ( PXL008 ) in Japan, China, South Korea, Taiwan and...
21:41 , Jun 28, 2017 |  BC Extra  |  Company News

Scholar Rock developing lead candidate for SMA

Scholar Rock LLC (Cambridge, Mass.) said it will develop its lead candidate SRK-015 to treat spinal muscular atrophy. CEO Nagesh Mahanthappa told BioCentury the company plans to submit an IND and begin Phase I testing...